PRESS RELEASE
News
-
-
PRESS RELEASE
Snipp Interactive Announces Execution of US$1.3 Million Contract for Customer Loyalty Programs for Multiple Brands of Leading FMCG Company
Snipp Interactive announces extension of loyalty program contract with leading FMCG manufacturer in the U.S., enhancing consumer engagement and program efficiency through innovative technology solutions -
PRESS RELEASE
Critical Elements Reports High Grade Polymettalic Results from the Nemaska Belt Properties, with Results up to 5.7% Cu, 0.82% Ni, 0.17% Co, 0.39 g/t Pt, 2.0 g/t Pd, 14.8 g/t Au and over 100 g/t Ag
Critical Elements Lithium Corporation announces latest exploration results from Nemaska Belt properties in Québec, showcasing high-grade nickel-copper-PGE and lithium-bearing spodumene mineralization. CEO confirms upcoming winter drill program to test new targets -
PRESS RELEASE
PeterPrint Expands into Germany with Digital Printing Processes for Modern Brands and Designers
Dutch company PeterPrint launches high-quality digital printing services in Germany, catering to design-oriented companies, e-commerce brands, and startups with exclusive digital printing for small runs. Innovative platform with unique features and focus on brand identity -
PRESS RELEASE
AI Leaders Came Together in Frankfurt for Exclusive Leadership Event with OpenAI, statworx, and AI Hub Frankfurt
AI leaders gathered in Frankfurt for an exclusive leadership event hosted by OpenAI, statworx, and AI Hub Frankfurt, discussing AI in business with real-world examples and insights on AI adoption and advancements -
-
PRESS RELEASE
Cantourage strengthens market presence in Poland with flower variety “Gelato 33”
Cantourage Group SE expands market presence in Poland with introduction of 'Gelato 33' strain from Canadian cultivator LOT420, in collaboration with Polish wholesaler PharmaVitae, as part of its European growth strategy -
-
PRESS RELEASE
Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on MaaT Pharma SACA with a BUY rating and EUR 17 price target. MaaT Pharma focuses on microbiome-based therapies for oncology, with high clinical impact and late-stage pipeline -
